Ibogaine.info

Costs vary widely between clinics and countries, and the figure tracks program length, the substance being treated, and above all the level of medical staffing and cardiac monitoring, not the comfort of the setting. Ask any provider for an itemised, written breakdown before paying a deposit, and be wary of a single lump-sum quote with no line for screening or monitoring. If a price looks low, check what has been left out.

There is no scientific evidence that microdosing reproduces the effects studied in ibogaine research. The anti-addictive effect described in the literature involves a single large ("flood") dose given under medical supervision. Iboga carries cardiac risk at meaningful doses regardless of framing, and home use bypasses exactly the screening and monitoring that make supervised treatment safer.

This is the central risk. Ibogaine prolongs the heart's QT interval and can trigger a potentially fatal arrhythmia called torsades de pointes. Most reported deaths have involved unsupervised settings or people who were never properly screened. A baseline 12-lead ECG, correction of electrolytes, and continuous cardiac monitoring are widely treated as the minimum standard, see the open-label safety study by Knuijver and colleagues (2022).

Common contraindications include pre-existing heart conditions, any medication that itself prolongs the QT interval, and significant liver impairment. This is not a checklist to self-assess, a responsible provider runs full cardiac and metabolic screening and will decline anyone who does not clear it. If a clinic is willing to proceed without that assessment, treat it as a red flag rather than convenience.

Because it appears to address the main danger directly. Stanford's MISTIC protocol co-administered magnesium to blunt ibogaine's QT prolongation and reported no cardiac events in its cohort of veterans with traumatic brain injury. That safety framing is a large part of why the approach has drawn serious scientific attention, and the study was published in Nature Medicine (2024).

Look for mandatory cardiac screening, continuous monitoring during the session, licensed medical staff physically present, honest and unprompted disclosure of the risks, and reviews on independent platforms rather than testimonials hosted on the clinic's own website. The clearest warning signs are the opposite: a provider who downplays the cardiac risk, skips screening, or guarantees results.

It is Schedule I in the United States, legal in Canada, and prescription-only in New Zealand. Clinics operate in Mexico, the Netherlands, South Africa and elsewhere in legal gray areas. Status is shifting as US policy changes, see the full legal status map for the country-by-country picture.

Only two randomised controlled trials on ibogaine for substance use disorders have ever been conducted. Observational data point to real short-term anti-addictive effects, but durable results depend heavily on integration and aftercare, and relapse is common without them. The honest summary is "promising but far from proven," which is why the current wave of state-funded trials matters.

Because those figures are almost always marketing, not research. Numbers like "90%+ resolution" typically come from a clinic's own website, self-reported and unaudited, sometimes "medically reviewed" by that same clinic's director. Genuine evidence is published in peer-reviewed journals and registered on ClinicalTrials.gov, where outcomes are far more modest and the caveats are stated openly. A useful rule: if a success rate isn't attached to a citation you can check, treat it as an advertisement.